Neuland Laboratories Limited (NSE: NEULANDLAB), a leading pharmaceutical manufacturer, has announced its financial results for the fiscal year ending March 31, 2026. The company reported a total income of ₹2053.1 crore for the year.
The Hyderabad-based company, which specialises in active pharmaceutical ingredients (APIs) and custom manufacturing solutions, noted significant growth in its financial performance. For the fourth quarter of FY26, Neuland Laboratories reported a total income of ₹788.7 crore, marking a 134.9% increase compared to ₹335.8 crore in the same quarter of the previous year.
The company’s Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) for Q4 FY26 stood at ₹319.4 crore, a substantial rise of 448.6% from ₹58.2 crore in Q4 FY25. The EBITDA margin also improved significantly to 40.5% from 17.3% in the corresponding quarter last year.
Profit Before Tax (PBT) for the fourth quarter was reported at ₹287.0 crore, a 636.6% increase from ₹39.0 crore in Q4 FY25. The PBT margin increased to 36.4% from 11.6% year-on-year.
Profit After Tax (PAT) for Q4 FY26 was ₹212.5 crore, a remarkable 666.3% growth compared to ₹27.7 crore in the same quarter last year.
Commenting on the results, Saharsh Davuluri, CEO and Managing Director of Neuland Laboratories, expressed satisfaction with the company’s performance, highlighting the strong business visibility and the strategic investments in peptide manufacturing and a new R&D centre.
Neuland Laboratories will hold an earnings call on May 12, 2026, at 17:30 IST to discuss the financial results and take questions from participants. The transcript will be available on the company’s website later.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).